Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Last trade$83.41
Day change-$0.98 (-1.16%)
Day range$83.20 – $85.46
Volume1,642,992
Market cap$34.29B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$34.29B
Price / earnings
13.79×
Price / book
10.38×
Price / sales
3.61×
EV / sales
4.42×
EV / EBITDA
10.42×
Profitability
Earnings per share
$6.12
Return on assets
16.48%
Return on equity
75.26%
Dividend yield
2.58%
Liquidity and leverage
Debt / equity
2.74×
Current ratio
2.35×
Quick ratio
1.4×
Cash ratio
0.5×
Cash flow
Price / cash flow
12.37×
Price / free cash flow
15.05×
Free cash flow
$2.28B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ZTS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.39B
$2.47B
$2.26B
$2.39B
$2.42B
$2.47B
$2.2B
$2.32B
Cost of revenue
$698M
$673M
$641M
$712M
$697M
$664M
$618M
$707M
Gross profit
$1.69B
$1.8B
$1.62B
$1.68B
$1.73B
$1.81B
$1.58B
$1.61B
Selling, general and administrative
$582M
$592M
$588M
$619M
$582M
$614M
$574M
$625M
Research and development
$174M
$173M
$180M
$199M
$175M
$166M
$162M
$186M
Total operating expenses
$830M
$873M
$821M
$866M
$793M
$843M
$768M
$847M
Operating income
$863M
$922M
$800M
$809M
$932M
$967M
$812M
$763M
Interest expense
-$62M
-$61M
-$62M
-$57M
-$58M
-$53M
-$54M
-$51M
Income before taxes
$729M
$866M
$758M
$761M
$886M
$912M
$773M
$732M
Income taxes
$138M
$175M
$157M
$158M
$165M
$186M
$171M
$151M
Net income
$591M
$691M
$601M
$603M
$721M
$726M
$602M
$581M
Net income attributable to common shareholders
$591M
$691M
$601M
$603M
$721M
$726M
$602M
$581M
EBITDA
$1.03B
$1.12B
$941M
$947M
$1.06B
$1.12B
$931M
$888M
Basic earnings per share
$1.44
$1.65
$1.42
$1.38
$1.63
$1.63
$1.34
$1.29
Diluted earnings per share
$1.44
$1.65
$1.42
$1.37
$1.63
$1.63
$1.34
$1.29
Recent news
Company coverage with links to the original publishers.
Zoetis announced USDA approval for Cytopoint Plus, a monoclonal antibody therapy providing 75 days of relief from allergic itch in dogs. The extended dosing interval is approximately 1.5 times longer than existing mAb options, expanding Zoetis' canine dermatology portfolio alongside Cytopoint, Apoquel, and Apoquel Chewable. Market uptake will depend on pricing, veterinary recommendations, and real-world performance.
Zoetis reported Q3 adjusted earnings of $1.75 per share, beating estimates of $1.51, with revenues of $2.39 billion exceeding expectations despite a 1% year-over-year decline. The company raised 2026 EPS guidance to $6.25-$6.35 and narrowed revenue outlook to $9.22-$9.32 billion. Companion animal demand remains pressured, but targeted promotions reduced dermatology market share losses, while livestock revenues grew 7% and diagnostics increased 13%.
The iShares U.S. Pharmaceuticals ETF (IHE) offers lower costs, higher dividend yield (1.4% vs 0.2%), and better 5-year returns (79% vs 38%) compared to the iShares Biotechnology ETF (IBB). IHE focuses on 53 established drugmakers with lower volatility, while IBB provides broader exposure to 243 biotech firms with higher risk. IHE may be preferable for income-focused investors, though IBB suits those seeking broader biotech sector exposure.
Mexico's animal healthcare market is projected to grow from USD 2.13 billion in 2025 to USD 3.34 billion by 2031, with a CAGR of 7.84%. Growth is driven by rising companion animal spending, expanding livestock production, stronger biosecurity requirements, and innovation in veterinary diagnostics. Key challenges include high costs, limited rural infrastructure, and counterfeit medicines.
Zoetis reported a 1% organic revenue decline in Q3 2026, pressured by lower veterinary clinic visits and generic competition in pet care. However, global livestock revenue grew 7% to $797 million, offsetting weakness. The company is deploying promotional strategies to defend market share in dermatology and relying on lifecycle innovations like Simparica Duo to extend core product franchises. Management expects continued macro headwinds into 2027 but maintains a long-term growth thesis centered on innovation and new therapeutic categories.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Oct 30, 2026
$0.53
Dec 1, 2026
recurring
Jul 20, 2026
$0.53
Sep 1, 2026
recurring
Apr 20, 2026
$0.53
Jun 2, 2026
recurring
Jan 20, 2026
$0.53
Mar 3, 2026
recurring
Oct 31, 2025
$0.50
Dec 2, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.